Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1994-11-02
1998-03-03
Walsh, Stephen
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
530350, 530413, 435 691, A61K 3817, C07K 14435
Patent
active
057234370
ABSTRACT:
The present invention relates, in general, to CD6 and, in particular, to a CD6 ligand present on the surface of thymic epithelial cells, monocytes, activated T cells and a variety of other cells types. The invention further relates to methods of inhibiting the interaction of CD6 and the CD6 ligand, and to the methods of screening componunds for their ability to inhibit that interaction.
REFERENCES:
Wee et al, "Characterization of a CD6 Ligand(s) Expressed on Human-and Murine-Derived Cell Lines and Murine Lymphoid Tissues", Cellular Immunology 158:353-364 (1994).
Aruffo et al, "The Lymphocyte Glycoprotein CD6 Contains a Repeated Domain Structure Characteristic of a New Family of Cell Surface and Secreted Proteins", J. Exp. Med. 174:949-952 (1991).
Kamoun et al, "A Novel Human T Cell Antigen Preferentially Expressed on Mature T Cells and Shared By Both Well and Poorly Differenitated B Cell Leukemias and Lymphomas", The Journal of Immunology 127(3):987-991 (1981).
Gangemi et al, "Anti-T12, An Anti-CD6 Monoclonal Antibody, Can Activate Human T Lymphocytes", The Journal of Immunology 143:2439-2447 (1989).
Morimoto et al, "2H1--A Novel Antigen Involved in T Lymphocyte Triggering", The Journal of Immunology, 140:2165-2170 (1988).
Wee et al, "Tyrosine Phosphorylation of CD6 by Stimulation of CD3: Augmentation by the CD4 and CD2 Coreceptors", J. Exp. Med. 177:219-223 (1993).
Soiffer et al, "Prevention of Graft-Versus-Host Disease by Selective Depletion of CD6-Positive T Lymphocytes from Donor Bone Marrow", Journal of Clinical Oncology 10(7):1191-1200 (1992).
Vollger et al, "Thymocyte Binding to Human Thymic Epithelial Cells is Inhibited by Monoclonal Antibodies to CD-2 and LFA-3 Antigens", The Journal of Immunology 138:358-363 (1987).
Swack et al, "Biosynthesis and Post-translational Modification of CD6, a T Cell Signal-transducing Molecule", The Journal of Biological Chemistry 266(11):7137-7143 (1991).
Pawelec and Buhring, "Monoclonal Antibodies to CD6 Preferentially Stimulate T-Cell Clones with .gamma./.delta. Rather Than .alpha./.beta. Antigen Receptors", Human Immunology 31:165-169 (1991).
Mayer et al, "Expression of the CD6 T lymphocyte differentiation antigen in normal human brain", Journal of Neuroimmunology 29:193-202 (1990).
Aruffo et al, "Granule membrane protein 140 (GMP140) binds to carcinomas and carcinoma-derived cell lines", Proc. Natl. Acad. Sci. USA 89:2292-2296 (1992).
Pesandro et al, "Antibody-Induced Antigenic Modulation is Antigen Dependent: Characterization of 22 Proteins on a Malignant Human B Cell", The Journal of Immunology 137(11):3689-3695 (1986).
Patel et al, "Human Thymic Epithelial Cells Express A Ligand for CD6 Which Mediates Binding to Mature Thymocytes", Clinical Res. 41(2):220A (1993).
Swack et al, "Structural Characterization of CD6: Properties of Two Distinct Epitopes Involved in T Cell Activation", Molecular Immunology 26(11):1037-1049 (1989).
Sims et al, "cDNA Expression Cloning of the IL-1 Receptor, a Member of the Immunoglobulin Superfamily", Science 241:585-589 (1988).
Aruffo Alejandro
Haynes Barton F.
Patel Dhavalkumar
Bristol--Myers Squibb Company
Duke University
Teng Sally P.
Walsh Stephen
LandOfFree
CD6 ligand does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with CD6 ligand, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and CD6 ligand will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2247697